Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

医学 超重 二甲双胍 糖尿病 内科学 2型糖尿病 临床终点 英国前瞻性糖尿病研究 胰岛素 内分泌学 随机对照试验 体质指数
作者
UK Prospective Diabetes,R R Holman,SE Manley,R. C. Turner,C A Cull,I Stratton,Matthews,Michael Gnant
出处
期刊:PubMed 卷期号:352 (9131): 854-65 被引量:4164
链接
标识
摘要

In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage.Of 4075 patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had raised fasting plasma glucose (FPG; 6.1-15.0 mmol/L) without hyperglycaemic symptoms after 3 months' initial diet. 753 were included in a randomised controlled trial, median duration 10.7 years, of conventional policy, primarily with diet alone (n=411) versus intensive blood-glucose control policy with metformin, aiming for FPG below 6 mmol/L (n=342). A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409). The primary outcome measures were aggregates of any diabetes-related clinical endpoint, diabetes-related death, and all-cause mortality. In a supplementary randomised controlled trial, 537 non-overweight and overweight patients, mean age 59 years, who were already on maximum sulphonylurea therapy but had raised FPG (6.1-15.0 mmol/L) were allocated continuing sulphonylurea therapy alone (n=269) or addition of metformin (n=268).Median glycated haemoglobin (HbA1c) was 7.4% in the metformin group compared with 8.0% in the conventional group. Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint, 42% for diabetes-related death (9-63, p=0.017), and 36% for all-cause mortality (9-55, p=0.011). Among patients allocated intensive blood-glucose control, metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021), and stroke (p=0.032). Early addition of metformin in sulphonylurea-treated patients was associated with an increased risk of diabetes-related death (96% increased risk [95% CI 2-275], p=0.039) compared with continued sulphonylurea alone. A combined analysis of the main and supplementary studies showed fewer metformin-allocated patients having diabetes-related endpoints (risk reduction 19% [2-33], p=0.033). Epidemiological assessment of the possible association of death from diabetes-related causes with the concurrent therapy of diabetes in 4416 patients did not show an increased risk in diabetes-related death in patients treated with a combination of sulphonylurea and metformin (risk reduction 5% [-33 to 32], p=0.78).Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DijiaXu应助猪猪hero采纳,获得10
3秒前
4秒前
悦耳静枫完成签到,获得积分10
4秒前
霍骁发布了新的文献求助10
5秒前
XAN关注了科研通微信公众号
6秒前
6秒前
7秒前
简因完成签到 ,获得积分10
8秒前
9秒前
11发布了新的文献求助10
10秒前
10秒前
11秒前
不学无术发布了新的文献求助10
13秒前
hanna完成签到 ,获得积分10
13秒前
14秒前
科研通AI5应助科研通管家采纳,获得10
14秒前
斯文败类应助科研通管家采纳,获得10
14秒前
小二郎应助科研通管家采纳,获得10
15秒前
领导范儿应助科研通管家采纳,获得10
15秒前
Orange应助科研通管家采纳,获得10
15秒前
香蕉觅云应助科研通管家采纳,获得10
15秒前
FashionBoy应助科研通管家采纳,获得10
15秒前
桐桐应助科研通管家采纳,获得10
15秒前
彭于晏应助科研通管家采纳,获得10
15秒前
慕青应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
爆米花应助科研通管家采纳,获得10
15秒前
czh应助科研通管家采纳,获得20
15秒前
qqshown完成签到,获得积分10
16秒前
16秒前
16秒前
16秒前
16秒前
18秒前
量子星尘发布了新的文献求助10
18秒前
XAN发布了新的文献求助10
19秒前
DijiaXu应助必过六级采纳,获得10
21秒前
小门发布了新的文献求助10
21秒前
22秒前
Afaq发布了新的文献求助10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136